X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5622) 5622
Publication (611) 611
Book Review (55) 55
Book Chapter (31) 31
Dissertation (17) 17
Conference Proceeding (6) 6
Magazine Article (2) 2
Reference (2) 2
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
sunitinib (4988) 4988
index medicus (3391) 3391
humans (3318) 3318
oncology (2819) 2819
cancer (1844) 1844
male (1759) 1759
female (1745) 1745
sorafenib (1556) 1556
middle aged (1463) 1463
carcinoma, renal cell - drug therapy (1394) 1394
kidney neoplasms - drug therapy (1325) 1325
aged (1307) 1307
renal cell carcinoma (1203) 1203
antineoplastic agents - therapeutic use (1175) 1175
interferon-alpha (1135) 1135
metastasis (1079) 1079
adult (981) 981
treatment outcome (963) 963
kidney neoplasms - pathology (947) 947
carcinoma, renal cell (921) 921
indoles - therapeutic use (901) 901
pyrroles - therapeutic use (890) 890
survival (887) 887
care and treatment (868) 868
tyrosine kinase inhibitor (798) 798
bevacizumab (784) 784
urology & nephrology (711) 711
renal-cell carcinoma (683) 683
endothelial growth-factor (679) 679
carcinoma, renal cell - pathology (676) 676
therapy (664) 664
everolimus (639) 639
angiogenesis (629) 629
pharmacology & pharmacy (610) 610
targeted therapy (607) 607
efficacy (599) 599
vascular endothelial growth factor (597) 597
animals (586) 586
prognosis (585) 585
tumors (582) 582
aged, 80 and over (572) 572
antineoplastic agents (568) 568
disease-free survival (550) 550
antineoplastic agents - adverse effects (546) 546
antimitotic agents (543) 543
chemotherapy (523) 523
retrospective studies (522) 522
analysis (519) 519
trial (508) 508
medicine & public health (506) 506
indoles - adverse effects (498) 498
protein kinase inhibitors - therapeutic use (498) 498
pyrroles - adverse effects (490) 490
niacinamide - analogs & derivatives (482) 482
drug therapy (481) 481
indoles - administration & dosage (468) 468
neoplasm metastasis (460) 460
kidney cancer (458) 458
pyrroles - administration & dosage (458) 458
pazopanib (455) 455
research (449) 449
tyrosine (439) 439
angiogenesis inhibitors - therapeutic use (438) 438
carcinoma, renal cell - secondary (435) 435
double-blind (434) 434
carcinoma (412) 412
tyrosine kinase inhibitors (387) 387
expression (370) 370
imatinib (368) 368
phase-iii trial (368) 368
hematology, oncology and palliative medicine (367) 367
phase-ii (364) 364
carcinoma, renal cell - mortality (363) 363
urology (361) 361
kidney neoplasms - mortality (349) 349
indoles - pharmacology (347) 347
safety (346) 346
pyrroles - pharmacology (344) 344
antineoplastic agents - administration & dosage (331) 331
antineoplastic combined chemotherapy protocols - therapeutic use (330) 330
vegf (328) 328
urologic and male genital diseases (317) 317
antineoplastic agents - pharmacology (315) 315
immunotherapy (314) 314
patients (308) 308
risk factors (308) 308
metastatic renal cell carcinoma (306) 306
antitumor-activity (305) 305
mice (304) 304
temsirolimus (300) 300
nephrectomy (297) 297
hypertension (296) 296
article (294) 294
health aspects (287) 287
protein kinase inhibitors - adverse effects (282) 282
molecular targeted therapy (275) 275
clinical trials (273) 273
su11248 (267) 267
imatinib mesylate (265) 265
cell line, tumor (263) 263
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5246) 5246
German (127) 127
French (124) 124
Spanish (42) 42
Korean (30) 30
Japanese (28) 28
Chinese (16) 16
Russian (15) 15
Czech (11) 11
Polish (9) 9
Turkish (6) 6
Hungarian (5) 5
Slovak (4) 4
Italian (2) 2
Catalan (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Ye, SL
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 10/2015, Volume 33, Issue 28, pp. 3220 - U215
Journal Article
Nature Medicine, ISSN 1078-8956, 06/2018, Volume 24, Issue 6, pp. 749 - 757
We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib... 
MEDICINE, RESEARCH & EXPERIMENTAL | MULTICENTER | PD-L1 EXPRESSION | BIOCHEMISTRY & MOLECULAR BIOLOGY | PHASE-III | SINGLE-ARM | CANCER | CELL BIOLOGY | PATHWAY | SUPPRESSOR-CELLS | NIVOLUMAB | TUMOR-GROWTH | ENDOTHELIAL GROWTH-FACTOR | Sunitinib - pharmacology | Bevacizumab - pharmacology | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Male | Gene Expression Profiling | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Aged, 80 and over | Adult | Female | Carcinoma, Renal Cell - drug therapy | Antibodies, Monoclonal - pharmacology | Kaplan-Meier Estimate | Treatment Outcome | Mutation - genetics | Sunitinib - adverse effects | Sunitinib - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Kidney Neoplasms - drug therapy | Development and progression | Dosage and administration | Angiogenesis inhibitors | Carcinoma, Renal cell | Comparative analysis | Drug therapy | Cell survival | Inflammation | Gene expression | Molecular chains | Bevacizumab | Metastases | Confidence intervals | Angiogenesis | Immune checkpoint | Immunotherapy | γ-Interferon | PD-L1 protein | Biomarkers | Bioindicators | Vascular endothelial growth factor | Clear cell-type renal cell carcinoma
Journal Article
The Lancet Oncology, ISSN 1470-2045, 03/2019, Volume 20, Issue 3, pp. e127 - e127
Journal Article
International Journal of Molecular Sciences, ISSN 1422-0067, 10/2019, Volume 20, Issue 19, p. 4949
Despite being infrequent tumors, the incidence and prevalence of pancreatic neuroendocrine tumors (P-NETs) has been rising over the past few decades. In recent... 
sunitinib | antiangiogenic | neuroendocrine tumors | resistance
Journal Article
Journal of Urology, ISSN 0022-5347, 10/2014, Volume 192, Issue 4, pp. 1079 - 1079
Journal Article
by Wu, Y and Wang, BL and Wang, JJ and Qi, S and Zou, FM and Qi, ZP and Liu, FY and Liu, QW and Chen, C and Hu, C and Hu, ZQ and Wang, AL and Wang, L and Wang, WC and Ren, T and Cai, YJ and Bai, MF and Liu, QS and Liu, J
JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0022-2623, 07/2019, Volume 62, Issue 13, pp. 6083 - 6101
Starting from our previously developed c-KIT kinase inhibitor CHMFL-KIT-8140, through a type II kinase inhibitor binding elements hybrid design approach, we... 
RESISTANCE | SUNITINIB | CHEMISTRY, MEDICINAL | MUTATIONS | IMATINIB
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2018, Volume 36, Issue 8, pp. 765 - 772
PurposeCabozantinib, an inhibitor of tyrosine kinases including MET, vascular endothelial growth factor receptors, and AXL, increased progression-free survival... 
TARGETED THERAPY | SURVIVAL | IMPACT | EVEROLIMUS | ONCOLOGY | GROWTH | SUNITINIB
Journal Article
Cancer, ISSN 0008-543X, 02/2011, Volume 117, Issue 3, pp. 534 - 544
BACKGROUND: Sunitinib and sorafenib are tyrosine kinase inhibitors that have important antitumor activity in metastatic renal cell carcinoma (mRCC).... 
sunitinib | renal cell carcinoma | sorafenib | hypothyroidism | predictive factors
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2018, Volume 29, Issue 10, pp. 2030 - 2032
Journal Article
European Urology, ISSN 0302-2838, 12/2018, Volume 74, Issue 6, pp. 841 - 841
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1/2018, Volume 81, Issue 1, pp. 163 - 169
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2017, Volume 35, Issue 35, pp. 3995 - 3997
Journal Article
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 09/2013, Volume 40, Issue 9, pp. 1241 - 1244
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 02/2019, Volume 25, Issue 4, pp. 1165 - 1173
Purpose: In the S-TRAC trial, adjuvant sunitinib prolonged disease-free survival (DFS) versus placebo in patients with loco-regional renal cell carcinoma at... 
BIOMARKERS | SURVIVAL | EFFICACY | ONCOLOGY | 1ST-LINE SUNITINIB | INDUCED TOXICITY | MARKERS | PROGNOSTIC NOMOGRAM | CANCER | SINGLE-NUCLEOTIDE POLYMORPHISMS | NEPHRECTOMY | sunitinib | renal cell carcinoma | pharmacogenomics | disease-free survival | adjuvant
Journal Article
European Urology, ISSN 0302-2838, 12/2017, Volume 72, Issue 6, pp. 984 - 985
Journal Article
Translational Cancer Research, ISSN 2218-676X, 02/2018, Volume 7, pp. S74 - S76
Journal Article
Oncotarget, ISSN 1949-2553, 05/2018, Volume 9, Issue 38, pp. 25277 - 25284
In this study, we examined the association between the pharmacokinetics (PK) level of sunitinib malate (SU) and its metabolite N-desethyl-sunitinib (DSU) in... 
Sunitinib | Pharmacokinetics | Renal cell carcinoma | N-desethyl-sunitinib
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.